Neurodevelopmental Disorder with Microcephaly, Hypotonia, and Absent Language

Executive Summary

Neurodevelopmental disorder with microcephaly, hypotonia, and absent language (NEDMHAL; OMIM #620038; MONDO:0859287) is an ultra-rare, severe autosomal recessive Mendelian disorder caused by biallelic hypomorphic missense variants in PSMB1, the gene encoding the non-catalytic β6 subunit of the 20S proteasome core. It was defined by Ansar et al., 2020 (PMID: 32129449), who found a homozygous PSMB1 c.307T>C, p.(Tyr103His) variant segregating with disease in two siblings of a consanguineous Pakistani family and validated causality in human SH-SY5Y cells and zebrafish.

The core phenotype is congenital/early-onset microcephaly, neonatal hypotonia, severe-to-profound intellectual disability, and absent expressive language, with global developmental delay, motor disability (often inability to walk), hearing impairment, and behavioral features (aggression, ADHD). Mechanistically, p.(Tyr103His) weakens the β6(PSMB1)–α5(PSMA5) subunit interface, destabilizing the 20S proteasome and reducing proteolytic capacity; the resulting proteostatic stress activates the integrated stress response and a type I interferon signature shared across "primary proteasomopathies" (PSMB1/PSMC1/PSMC3/PSMD12/PSMD11), derailing prenatal brain development.

There is no disease-modifying therapy — management is supportive and multidisciplinary — and prevention rests on genetic counseling and carrier/prenatal/preimplantation testing. A key nuance: the causal SNV is not yet classified pathogenic in ClinVar (same-codon changes are VUS), so the gene–disease relationship rests on strong functional/segregation evidence rather than accumulated clinical classifications; ClinVar "pathogenic" entries in the region are large 6q-terminal CNVs of a distinct contiguous-gene syndrome.

1. Disease Information

Overview. NEDMHAL is a rare autosomal recessive neurodevelopmental disorder caused by biallelic hypomorphic variants in PSMB1, a gene encoding a β-type subunit of the 20S proteasome core. It is a congenital "primary proteasomopathy": impaired proteasome assembly/function during brain development produces a static encephalopathy dominated by microcephaly, muscular hypotonia, severe global developmental delay/intellectual disability, and absent expressive language, frequently with motor disability (inability to walk), hearing impairment, and behavioral disturbance. [human clinical; computational]

• "PSMB1 encodes a β-type proteasome subunit (i.e. β6)… PSMB1/β6 pathogenic variants are the cause of a recessive disease with ID, microcephaly and developmental delay due to abnormal proteasome assembly." — Ansar et al., 2020 (PMID 32129449).
• Authoritative concept definition (NCBI MedGen CUI C5774216 / UID 1823989): "Neurodevelopmental disorder with microcephaly, hypotonia, and absent language (NEDMHAL) is a severe autosomal recessive disorder characterized by the constellation of these features. Behavioral problems and hearing loss are also present (Ansar et al., 2020)." — confirms severity, autosomal recessive inheritance, and the additional behavioral/hearing features, and that OMIM #620038 is anchored to Ansar et al., 2020.

Key identifiers. | Resource | ID | |---|---| | MONDO | MONDO:0859287 | | OMIM (phenotype) | 620038 | | OMIM (gene, PSMB1) | 602017 | | UMLS / MedGen | C5774216 / CUI 1823989 (MedGen 1823989) | | HGNC (gene) | HGNC:9537 | | NCBI Gene | 5689 | | Ensembl | ENSG00000008018 | | UniProt (protein) | P20618 |

• Orphanet: No NEDMHAL-specific ORPHAcode was identified; the condition falls within Orphanet's broad "rare genetic intellectual disability / rare developmental defect" groupings. (Not established — flagged as unavailable.)
• ICD-11: No disease-specific code; maps to the neurodevelopmental block (e.g., LD90.Y "Other specified developmental anomalies" / 6A00 "Disorders of intellectual development") plus 5C51-range for proteostasis defects. (No dedicated code.)
• ICD-10: No specific code (would be coded via Q02 microcephaly / F79 unspecified intellectual disability / R62.0 developmental delay). (No dedicated code.)
• MeSH: No dedicated descriptor; nearest concepts are "Neurodevelopmental Disorders," "Microcephaly," "Muscle Hypotonia," "Intellectual Disability."

Synonyms / alternative names: NEDMHAL; PSMB1-related neurodevelopmental disorder; PSMB1-associated primary proteasomopathy; "microcephaly, intellectual disability, developmental delay and short stature due to PSMB1 deficiency" (descriptive, per Ansar et al. 2020).

Data provenance: Disease-level aggregated resources (OMIM, MONDO, HPO/Monarch) combined with individual-patient case reports (EHR/clinical exome workup). Not derived from large EHR cohorts; it is a case-report/case-series–level entity.

2. Etiology

Primary cause — genetic. Biallelic (homozygous or compound-heterozygous) pathogenic variants in PSMB1. The index report identified a homozygous missense variant p.(Tyr103His) (NM_002793) segregating with disease under an autosomal recessive model in a consanguineous Pakistani family. [human clinical]

• "we have identified homozygosity for p(Tyr103His) in the PSMB1 gene (Genbank NM_002793) that segregated with the disease phenotype." — PMID 32129449.

Genetic risk factors. - Causal variant: PSMB1 p.(Tyr103His) (hypomorphic missense) — necessary and sufficient in the biallelic state. - Susceptibility/predisposing factor: parental consanguinity and regional founder homozygosity dramatically increase the risk of this recessive disorder. [human clinical] - Modifier genes: none formally identified for NEDMHAL. By analogy to the proteasomopathy family, the residual output of the ubiquitin–proteasome system and stress-response gene background (e.g., ISR/PKR, interferon-pathway genes) are plausible modifiers. (Not established for PSMB1.)

Environmental risk factors: None known. This is a monogenic disorder with no established toxic, infectious, occupational, dietary, or lifestyle contribution. Age and sex are not established risk factors; family history/consanguinity is the key non-molecular risk indicator.

Protective factors: No genetic or environmental protective factors identified. In principle, a normal (wild-type) PSMB1 allele is fully protective (recessive inheritance → heterozygous carriers are clinically unaffected).

Gene–environment interactions: None documented. (Not applicable/none established.)

3. Phenotypes

Curated HPO annotations (MONDO:0859287 / OMIM:620038, via Monarch) plus the primary case series. Onset is congenital/neonatal-to-infantile; severity is severe; course is static (non-progressive). Frequencies are qualitative given the very small number of reported patients (exact percentages not established).

• "…two siblings with phenotypic signs, including intellectual disability (ID), developmental delay and microcephaly… a recessive disease with ID, microcephaly and developmental delay." — PMID 32129449.

Quality-of-life impact: Profound. Absent language, severe intellectual disability, and non-ambulation imply lifelong dependence for all activities of daily living; behavioral features (aggression, ADHD) add caregiver burden. Formal QoL instruments (EQ-5D, PROMIS, disease-specific tools) have not been applied to this ultra-rare disorder.

4. Genetic / Molecular Information

Causal gene. PSMB1 — "proteasome 20S subunit beta 1"; HGNC:9537; NCBI Gene 5689; Ensembl ENSG00000008018; gene OMIM 602017; locus 6q27 (GRCh38 chr6:170,535,120–170,553,307). Protein: UniProt P20618, "Proteasome subunit beta type-1," 241 aa (systematic proteasome subunit name β6). [computational]

Pathogenic variants. - Reported variant: NM_002793.4:c.307T>C, p.(Tyr103His) — missense, homozygous, autosomal recessive (Ansar et al. 2020). ACMG classification consistent with pathogenic/likely pathogenic given segregation + functional evidence (in vitro proteasome-assembly defect + zebrafish model). [human clinical; in vitro; model organism] - Variant type/class: missense (hypomorphic). Frameshift/nonsense biallelic (complete null) genotypes have not been reported in this disorder, consistent with predicted non-viability of complete PSMB1 loss. - ClinVar reality-check (this iteration): As of query, ClinVar contains no classified pathogenic single-nucleotide PSMB1 variant for NEDMHAL — all PSMB1 SNVs are Uncertain significance or Likely benign (e.g., p.Met7Val, p.Arg66Gln, p.Arg128Cys, and notably p.Tyr103Cys (c.308A>G) as VUS at the same codon as the disease allele). Every ClinVar record labelled "Pathogenic/Likely pathogenic" in the PSMB1 region is a large 6q25–q27 terminal deletion/duplication CNV (contiguous-gene 6q-terminal deletion syndrome), not isolated PSMB1 disease. The gene–disease relationship therefore currently rests on the primary functional study (segregation + in-vitro proteasome-assembly defect + zebrafish), i.e., strong PS3-type functional evidence rather than accumulated clinical classifications. The occurrence of two independent nucleotide changes at Tyr103 (His via c.307T>C; Cys via c.308A>G) suggests this residue, near the β6–α5 interface, is a functionally sensitive/possible hotspot. [computational; human clinical] - Allele frequency: p.(Tyr103His) is ultra-rare/absent-to-singleton in gnomAD (population frequency not enriched); precise gnomAD count not established here but consistent with a private/founder recessive allele. - Somatic vs germline: germline (constitutional, inherited from carrier parents). - Functional consequence: loss of function at the pathway level — the variant impairs β6 processing and its incorporation into the proteasome, destabilizing the 20S core and reducing proteasome activity (i.e., partial loss of proteolytic capacity), rather than a gain-of-function or dominant-negative mechanism. [in vitro]

• "this variant weakens the interactions between PSMB1/β6 and PSMA5/α5 proteasome subunits and thus destabilizes the 20S proteasome complex… affects both the processing of PSMB1/β6 and its incorporation into proteasome, thus impairing proteasome activity." — PMID 32129449.

Population constraint (gnomAD, GRCh38). PSMB1 is loss-of-function intolerant: pLI = 0.968, LOEUF (oe_lof upper) = 0.52, observed/expected LoF = 0.28, lof_z = 3.09; missense is unconstrained (mis_z = 0.45, oe_mis = 0.94). Interpretation: complete biallelic loss is likely embryonic-lethal; the recessive disease arises from hypomorphic missense alleles that reduce but do not abolish proteasome function. [computational]

Modifier genes: none established. Epigenetic information: no disease-specific DNA-methylation/histone signature reported for PSMB1-NEDMHAL (episignatures have not been defined). (Not established.) Chromosomal abnormalities: none; this is a single-gene point-mutation disorder (no recurrent CNV at 6q27 implicated for NEDMHAL). Note the distinct proteasome-CNV disorder at 3q27.1 involves PSMD2 (PMID 41804662) — a different entity.

Suggested annotations: HGNC:9537 (PSMB1); GO molecular/complex terms below.

5. Environmental Information

• Environmental factors: None known to cause or trigger NEDMHAL (no toxin, radiation, pollution, or occupational association). (Not applicable — monogenic disorder.)
• Lifestyle factors: None. (Not applicable.)
• Infectious agents: None causal. Note the mechanistic irony: the disorder features a type I interferon (antiviral-type) signature driven intrinsically by proteostatic stress, not by any infection (see Section 6). (No infectious etiology.)

6. Mechanism / Pathophysiology

Core defect (upstream). Hypomorphic PSMB1/β6 → impaired β6 maturation and incorporation into the nascent 20S core → destabilized 20S proteasome and reduced assembly of functional 26S proteasomes → reduced ubiquitin-dependent proteolytic capacity. [in vitro; computational]

Downstream cascade. 1. Accumulation of ubiquitinated/misfolded/damaged proteins → disturbed proteostasis and protein aggregation. 2. Activation of stress responses, including the integrated stress response (ISR) via the kinase PKR, and a persistent type I interferon (IFN) gene signature — a shared hallmark across primary proteasomopathies. [in vitro; human clinical] 3. Impaired protein turnover in neural progenitors and neurons during a period of intense proliferation and differentiation → reduced brain growth (microcephaly, reduced brain size) and disrupted neuronal maturation/connectivity → severe NDD and absent language.

• "both syndromes show molecular similarities with protein aggregation, activated stress responses, metabolic imbalance and dysregulated type I interferon signalling." — Wolfgramm et al., 2026 review (PMID 42370079).
• "PSMD11 loss of function resulted in impaired 26S proteasome assembly and the acquisition of a persistent type I interferon (IFN) gene signature, mediated by the integrated stress response (ISR) protein kinase R (PKR)." — Deb et al., 2024 (PMID 38866022) [family-level mechanism].

Molecular pathways / cellular processes. Ubiquitin–proteasome system (UPS); proteasome assembly; proteasome-mediated ubiquitin-dependent protein catabolism; cellular response to unfolded/misfolded protein; type I IFN response; ISR/eIF2α signaling. Metabolic imbalance is described at the family level. Protein dysfunction: structural destabilization of the 20S core via weakened β6(PSMB1)–α5(PSMA5) subunit interface (loss of proteolytic function; secondary aggregation of substrates). Immune involvement: sterile, cell-intrinsic type I interferon activation (autoinflammatory-adjacent), distinguishing proteasomopathies from classical infections/immunodeficiencies. Tissue-damage mechanism: proteotoxic/oxidative-type stress in developing neural tissue rather than ischemia/fibrosis. Molecular profiling: transcriptomic type I IFN signatures are documented in the proteasomopathy family; NEDMHAL-specific omics (proteomics/metabolomics/single-cell/spatial) are not yet published.

Causal chain summary: PSMB1 p.(Tyr103His) → β6 misincorporation → 20S destabilization → ↓26S proteasome activity → ubiquitinated-protein accumulation/aggregation → ISR (PKR) + type I IFN → impaired neural proliferation/homeostasis → microcephaly + severe NDD + absent language.

Suggested ontology terms. - GO biological process: proteasome assembly (GO:0043248); proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161); response to type I interferon (GO:0034340); integrated stress response signaling (GO:0140467); cellular response to unfolded protein (GO:0034620). - GO cellular component: proteasome core complex (GO:0005839); proteasome complex (GO:0000502); cytosol (GO:0005829); nucleoplasm (GO:0005654). - GO molecular function: threonine-type endopeptidase activity (GO:0004298) [complex-level]. - CL cell types: neural progenitor/radial glial cell (CL:0011020), neuron (CL:0000540), glutamatergic neuron (CL:0000679). - CHEBI: ubiquitin-tagged substrates; bortezomib (CHEBI:52717) and other proteasome inhibitors (research tools, not therapeutics here).

7. Anatomical Structures Affected

• Organ level (primary): Brain (UBERON:0000955) — reduced size/microcephaly; cerebrum/cerebral cortex (UBERON:0000956) and overall brain growth. Nervous system (UBERON:0001016) is the primary system. [human clinical; model organism]
• Secondary/associated: Ear/auditory system (hearing impairment; UBERON:0001690 ear); musculoskeletal/skeletal growth (short stature; hypotonia affecting skeletal muscle UBERON:0001134); eye (UBERON:0000970) — microphthalmia documented in the zebrafish model (human ocular involvement not firmly established).
• Body systems: predominantly central nervous system; secondarily sensory (auditory), musculoskeletal, and growth/endocrine (short stature).
• Tissue/cell level: nervous tissue; neural progenitor cells and neurons of the developing cortex are the presumptive vulnerable populations (high proteostatic demand). CL terms: CL:0011020 (radial glial/neural progenitor), CL:0000540 (neuron).
• Subcellular level: the proteasome core complex (GO:0005839) within the cytoplasm (GO:0005737/GO:0005829) and nucleus (GO:0005634) — PSMB1/P20618 localizes to both compartments.
• Localization/lateralization: brain involvement is bilateral/symmetric (global reduction in brain volume), not focal or lateralized.

8. Temporal Development

• Onset: Congenital / neonatal-to-early-infantile. Hypotonia is often neonatal; microcephaly may be congenital (primary) or evolve postnatally; developmental delay becomes apparent in infancy; language fails to emerge in childhood. Onset pattern is insidious/chronic (a fixed developmental abnormality rather than an acute event). [human clinical]
• Progression: Static (non-progressive) encephalopathy. No evidence of neurodegeneration or regression is reported; deficits are stable and lifelong. Disease duration is chronic/lifelong. Progression rate is therefore not applicable in a degenerative sense.
• Disease stages: not staged (non-neoplastic, non-progressive). Functionally: neonatal hypotonia → infantile developmental delay/microcephaly recognition → childhood confirmation of absent language, severe ID, non-ambulation, behavioral features.
• Patterns: No remission (developmental deficits are fixed). Critical period: prenatal-to-early-postnatal neurodevelopmental window, when proteasome demand in proliferating neural tissue is highest — the presumptive window of vulnerability and, theoretically, the window in which any future intervention would need to act.

9. Inheritance and Population

• Inheritance: Autosomal recessive (biallelic PSMB1). Heterozygous carriers are unaffected. [human clinical]
• Penetrance: presumed complete in the biallelic state (based on the single informative family, both affected siblings homozygous). Formal penetrance estimates unavailable.
• Expressivity: likely variable (as in other proteasomopathies), but insufficient patients to quantify.
• Genetic anticipation: Not applicable (not a repeat-expansion disorder).
• Germline mosaicism: not reported.
• Founder effects / consanguinity: the reported allele arose in a consanguineous Pakistani family via homozygosity-by-descent; consanguinity is the principal risk context. Population-specific founder status not formally established.
• Carrier frequency: not established; expected very low given PSMB1 LoF-intolerance and rarity of hypomorphic alleles.
• Epidemiology: Ultra-rare. Prevalence and incidence are not established (only a handful of reported individuals worldwide; too few for rate estimates). Likely far below 1/1,000,000.
• Population demographics: first described in a South Asian (Pakistani) consanguineous family; no established ethnic predilection beyond the elevated recessive-disease risk in consanguineous populations. Sex ratio: no sex bias expected for an autosomal recessive gene (reported index siblings; formal ratio unavailable). Age distribution: presents in infancy/childhood; affected individuals are children/young people at description.

10. Diagnostics

Genetic testing is the diagnostic cornerstone (there is no biochemical newborn-screening marker). - Recommended approach: Whole-exome sequencing (WES) or whole-genome sequencing (WGS), ideally trio-based, is the highest-yield strategy for this genetically nonspecific NDD phenotype; homozygosity mapping is a useful adjunct in consanguineous families (as used in the index discovery). [human clinical] - Gene panels: PSMB1 is included on comprehensive intellectual-disability/NDD and (increasingly) proteasomopathy panels; single-gene testing is appropriate only when the phenotype is highly specific. - CMA / karyotype / FISH: used to exclude copy-number and cytogenetic causes of microcephaly + NDD; will not detect the PSMB1 point mutation. Interpretation caveat: ClinVar's "pathogenic" calls overlapping PSMB1 are all large 6q25–q27 terminal deletions/duplications — a distinct contiguous-gene (6q-terminal deletion) syndrome in which PSMB1 is only one of many affected genes; these must not be conflated with biallelic point-variant NEDMHAL. A separate 3q27.1 microdeletion (involving PSMD2) is another distinct proteasome-related CNV disorder (PMID 41804662). - Mitochondrial DNA / repeat-expansion testing: not indicated (not a mitochondrial or repeat-expansion disease). - Variant interpretation aids: ClinVar, ClinGen, gnomAD (allele frequency), and functional confirmation (proteasome-assembly/activity assays in patient cells).

Supportive clinical tests. - Imaging: Brain MRI to document microcephaly and any structural anomaly (the index/model data emphasize reduced brain size; cerebral/cerebellar atrophy has been described in an overlapping severe UPS phenotype). [human clinical] - Audiology: hearing assessment (BAER/audiometry) given hearing impairment. - EEG: if seizures are suspected (seizures are prominent in some related proteasomopathies/UPS disorders; not a defining NEDMHAL feature). - Auxology: growth monitoring (short stature), head-circumference tracking. - Research/omics biomarkers: a type I interferon signature (ISG transcript score in blood) and reduced proteasome chymotrypsin-like activity / accumulated ubiquitin–protein conjugates in patient cells are promising research biomarkers for proteasomopathies, not yet validated diagnostics for NEDMHAL. [in vitro; human clinical]

Clinical criteria / differential diagnosis. No formal diagnostic criteria; diagnosis = compatible phenotype + biallelic pathogenic PSMB1 variants. Differential diagnosis includes: - Other primary proteasomopathies: PSMC1, PSMC3 (PMID 37256937), PSMD11 (PMID 38866022), PSMD12 (Stankiewicz–Isidor syndrome), POMP; and CNV/PSMD2 (PMID 41804662). - Other UPS/ubiquitin disorders with overlapping microcephaly/absent-speech/hypotonia: OTUD6B (PMID 28343629), FBXO11 (PMID 30057029). - Broad microcephaly-with-ID differentials (e.g., primary microcephaly genes) and syndromic ID (e.g., Cohen, Angelman when absent speech + behavior predominate) — distinguished by gene-specific testing.

Screening: No population newborn screening (no metabolite). Relevant screening is carrier/cascade testing in families and prenatal/preimplantation genetic testing once the familial variant is known.

11. Outcome / Prognosis

• Survival/mortality: Not established. No survival, life-expectancy, or mortality-rate data exist for this ultra-rare disorder. Prognosis for neurodevelopmental function is poor (severe fixed disability).
• Morbidity/disability: Severe, lifelong. Absent language, severe intellectual disability, and frequent non-ambulation predict full dependence for daily care; hearing impairment and behavioral difficulties (aggression, ADHD) add morbidity. ICF-level: profound limitations in communication, mobility, and self-care.
• Disease course: Static; complications are those of severe neurodisability (e.g., feeding difficulty/aspiration, orthopedic sequelae of hypotonia/immobility, communication and behavioral challenges). Recovery potential: none for the core developmental deficits; supportive/rehabilitative care can improve function and comfort.
• Prognostic factors: presumably genotype-related residual proteasome activity (hypomorphic vs more severe alleles) and severity of microcephaly; formal prognostic models/biomarkers are not established. A high type I IFN signature is a candidate severity/activity biomarker at the family level.
• QoL measures: none applied specifically. (Not available.)

12. Treatment

There is no disease-specific or curative therapy. Management is supportive, multidisciplinary, and symptom-directed. [human clinical — standard of care for severe NDD]

• Supportive/rehabilitative (mainstay):
• Physical therapy (NCIT:C15367) and occupational therapy (NCIT:C15220) for hypotonia, motor delay, contracture prevention.
• Speech and language therapy / AAC (augmentative-alternative communication) for absent language.
• Special education and developmental/early-intervention services.
• Nutritional support/feeding management; monitoring for aspiration.
• Hearing aids / audiologic management for hearing impairment (NCIT:C50075 hearing aid).
• Pharmacotherapy (symptomatic only):
• Antiseizure medications if seizures occur (none disease-specific).
• Behavioral/ADHD and aggression management per standard pediatric neurodevelopmental guidelines (behavioral therapy first-line; pharmacologic agents as indicated).
• No pharmacogenomic guidance specific to PSMB1.
• Advanced/targeted/experimental therapeutics: None approved or in trials for NEDMHAL. Gene therapy, cell therapy, RNA-based therapy, and small-molecule proteostasis modulators are conceptual only. At the mechanistic/family level, the type I IFN/ISR axis (e.g., JAK inhibition for IFN-driven proteasome-associated autoinflammatory syndromes; ISR modulators) is a rational research direction, but not validated for the neurodevelopmental proteasomopathies and not applicable to already-completed brain development. (Experimental — no NCT identifiers for NEDMHAL.)
• Treatment outcomes / adverse events: Not applicable (no disease-specific therapy).
• Treatment strategy: Individualized supportive care coordinated by pediatric neurology, clinical genetics, rehabilitation medicine, audiology, and developmental pediatrics; genetic counseling for the family.

Suggested NCIT intervention terms: Physical Therapy (C15367), Occupational Therapy (C15220), Speech Therapy (C15311), Supportive Care (C15277), Genetic Counseling (C15687).

13. Prevention

• Primary prevention: Not achievable at the individual biological level (constitutional genetic disease). Population-level risk reduction relates to consanguinity awareness/education and genetic counseling in high-risk communities.
• Secondary prevention / early detection: Early developmental surveillance (head circumference, tone, milestones) enables earlier diagnosis and initiation of supportive interventions; no biochemical newborn screen exists.
• Tertiary prevention: Preventing complications of severe neurodisability (aspiration precautions, orthopedic surveillance, seizure and behavioral management, hearing optimization).
• Genetic screening/counseling (most relevant):
• Carrier and cascade testing for at-risk relatives once the familial PSMB1 variant is known.
• Prenatal diagnosis and preimplantation genetic testing (PGT-M) available for couples with a prior affected child (25% recurrence risk per pregnancy for two carriers).
• Genetic counseling to convey recurrence risk, consanguinity implications, and reproductive options (NSGC/ACMG frameworks).
• Immunization / public-health / environmental / prophylaxis measures: Not applicable to a monogenic disorder.

14. Other Species / Natural Disease

• Taxonomy / conservation: PSMB1 is deeply conserved with a single ortholog from yeast to human, reflecting an essential proteostasis role. Orthologs (NCBI GeneID): mouse Psmb1 (19170; Mus musculus, NCBITaxon:10090), rat Psmb1 (94198; NCBITaxon:10116), zebrafish psmb1 (445413; Danio rerio, NCBITaxon:7955), Drosophila melanogaster (39855; NCBITaxon:7227), Caenorhabditis elegans (176161; NCBITaxon:6239), S. cerevisiae PRE3 (852239; NCBITaxon:4932), Xenopus (394589), chicken (421551), plus dog, cow, macaque, and chimpanzee orthologs. [computational]
• Natural disease in other species: No naturally occurring PSMB1 Mendelian disease is catalogued in companion animals or wildlife (no OMIA entry identified). (Not established.)
• Comparative biology: Because the gene and the 20S proteasome architecture are conserved, the disease mechanism (proteasome-assembly deficiency → proteostatic stress) is expected to be evolutionarily conserved; this underpins cross-species modeling. Zoonotic/cross-species transmission: not applicable (non-transmissible genetic disorder).

15. Model Organisms

• Zebrafish (Danio rerio), single ortholog psmb1 (GeneID 445413) — the published disease model. CRISPR/Cas9 knockout and morpholino knockdown produced microcephaly, microphthalmia, and reduced brain size, recapitulating the core human microcephaly/brain-growth phenotype and providing in-vivo causal support. [model organism]
• "CRISPR/Cas9 mutagenesis or morpholino knock-down of the single psmb1 zebrafish orthologue resulted in microcephaly, microphthalmia and reduced brain size." — PMID 32129449.
• In-vitro/cellular models: Human SH-SY5Y neuroblastoma cells expressing p.(Tyr103His) demonstrated impaired β6 processing/incorporation and reduced proteasome activity; patient-derived cells (fibroblasts/PBMCs) are the standard substrate for proteasome-activity assays and IFN-signature profiling across proteasomopathies. [in vitro; human clinical]
• Mammalian (mouse/rat) models: A PSMB1-specific NEDMHAL mouse model is not reported; constitutive Psmb1 null is predicted to be embryonic-lethal (consistent with high LoF-intolerance), so conditional/hypomorphic or knock-in (p.Tyr103His-equivalent) strategies would be required. Orthologs available at MGI (mouse 19170) and RGD (rat 94198).
• Invertebrate models (family-level): Proteasome-NDD mechanisms have been modeled in Drosophila (e.g., depletion of the PSMD11 ortholog Rpn6 compromised reversal learning; PMID 38866022) — illustrating cognitive-relevant readouts transferable to PSMB1 study.
• iPSC/organoid models: Not yet published for PSMB1; cerebral organoids are a logical future platform to model microcephaly and the neurodevelopmental IFN/ISR response.
• Model characteristics/limitations: Zebrafish captures microcephaly/brain-size and eye phenotypes but not higher cognition/language; cell models capture the biochemical proteasome defect but not tissue-level neurodevelopment. Resources: ZFIN (zebrafish), MGI, RGD, FlyBase, WormBase, SGD.

Evidence Summary (key PMIDs)

Proposed Follow-up Experiments / Actions

1. Expand the patient cohort via GeneMatcher/Matchmaker Exchange and consanguineous-population NDD sequencing to identify additional biallelic PSMB1 families, define the full allelic spectrum, and quantify phenotype frequencies, penetrance, and expressivity.
2. Formally classify p.(Tyr103His) in ClinVar/ClinGen by assembling ACMG/AMP evidence — functional (PS3), segregation (PP1), and constraint (PM2) — to close the current interpretation gap for diagnostic laboratories.
3. Measure the type I interferon / ISG signature in patient PBMCs and fibroblasts to test whether NEDMHAL shares the IFN-I biomarker of PSMC3/PSMD11 proteasomopathies and to provide a candidate diagnostic/severity biomarker.
4. Build iPSC-derived neurons and cerebral organoids from patients to model human microcephaly and the neurodevelopmental ISR/IFN response, and to screen proteostasis-enhancing or IFN-modulating candidate agents.
5. Generate a hypomorphic knock-in mouse (p.Tyr103His-equivalent, given predicted null lethality) to study brain growth, behavior/cognition, and candidate therapeutics in vivo.
6. Conduct a brain-imaging and audiology natural-history study across identified cases to characterize the structural brain phenotype, hearing-loss trajectory, and prognostic factors.
7. Explore mechanism-based therapeutics (proteostasis enhancers; JAK/IFN pathway modulation) in cellular and animal models, with explicit attention to the prenatal critical window in which the neurodevelopmental damage occurs.

Limitations

• Very small human evidence base (primarily one consanguineous family); phenotype frequencies, penetrance/expressivity, epidemiology, natural history, and prognosis are qualitative or unavailable.
• Some features (e.g., microphthalmia, precise MRI spectrum) derive from the model organism or from related proteasomopathies, and may not generalize to every PSMB1 patient.
• No NEDMHAL-specific omics, biomarker validation, therapeutic trials, mammalian genetic model, or Orphanet/ICD code currently exists.
• Additional patients and functional studies are needed to define the allelic and phenotypic spectrum and to test whether ISR/IFN-targeting strategies have any translational value.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.